ライフサイエンスコーパス: glycolic acid

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 e response compared with poly(lactic acid-co-glycolic acid).

2 ive poly-beta amino ester and poly lactic-co-glycolic acid.

3 lymerisation reactions using amino acids and glycolic acid.

4 cord of clinical translation, poly(lactic-co-glycolic) acid.

5 ant, and plasticizer solvents, polylactic-co-glycolic acid (30% by solids volume), and regolith simul

6 SNAP) was encapsulated within poly(lactic-co-glycolic acid) 50:50 (PLGA) microspheres by using a soli

7 -based ILs (1 week); (2) bare poly(lactic-co-glycolic acid) (50:50, acid terminated) Resomer 504H (PL

8 ability of Fe(CN)6(3-) to oxidize DHEThDP to glycolic acid along with ThDP regeneration.

9 When biodegradable polymers poly(lactic-co-glycolic) acid and polylactic acid were included in the

10 we present a novel polymer of poly(lactic-co-glycolic) acid and polyvinyl alcohol that can serve as a

11 system containing a blend of poly(lactic-co-glycolic acid) and a representative poly(beta-amino) est

12 cles that perform better than poly(lactic-co-glycolic acid) and iron oxide, two commonly studied mate

13 odegradable polymers such as poly (lactic-co-glycolic acid) and polycaprolactone have been used to fo

14 tion of diblock copolymers of poly(lactic-co-glycolic acid) and polyethylene glycol (PLGA-PEG) using

15 o 50% (w/w) sirolimus drug in poly(lactic-co-glycolic acid) and were prepared on both MP35N metal all

16 fluorescently labeled silica, poly(lactic-co-glycolic acid), and polystyrene nanoparticles administer

17 to undergo rapid oxidation to form glyoxal, glycolic acid, and glyoxylic acid, but the formation of

18 icated by emulsification with poly(lactic-co-glycolic acid) as a core material and, in some cases, po

19 poly(ethylene glycol); PLGA = poly(lactic-co-glycolic acid)) assembled from small AuNRs (dimension: a

20 of aptamer (Apt)-targeted poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) nano

21 of thermosensitive hydrogels (poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-

22 d using biodegradable diblock poly(lactic-co-glycolic acid)-b-polyethyleneglycol and poly(lactic-co-g

23 cid)-b-polyethyleneglycol and poly(lactic-co-glycolic acid)-b-polyethyleneglycol collagen IV-targeted

24 dichloride in a biocompatible poly(lactic-co-glycolic acid)-b-polyethyleneglycol platform.

25 evant parameters, we report a poly(lactic-co-glycolic acid) based curcumin nanoparticle formulation (

26 acids liberated by the biodegradable lactic/glycolic acid-based polyester, we coincorporated into th

27 f streptavidin-functionalized poly(lactic-co-glycolic acid) beads with biotinylated bovine serum albu

28 cs by blending a targeted poly(d,l-lactic-co-glycolic acid)-block (PLGA-b)-poly(ethylene glycol) (PEG

29 patible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG)

30 r and carboxyl-terminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in

31 lubilization of EpoB in a poly(d,l-lactic-co-glycolic acid)-block-poly(ethylene glycol)-block-poly(d,

32 Poly(lactic acid)-co-(glycolic acid)-block-poly(ethylene glycol)-block-poly(la

33 (PEG-b-PLA) micelles and poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol)-block-poly(D,L

34 e (NP) based on biodegradable poly(lactic-co-glycolic acid)-block-polyethyleneglycol functionalized w

35 carboxyl functionalization of poly(lactic-co-glycolic acid) can achieve great material homogeneity in

36 tains a core of biodegradable poly(lactic-co-glycolic acid), cholesteryl oleate, and a phospholipid b

37 a moldable alloplastic graft, Poly Lactic-Co-Glycolic Acid-Coated B-Tricalcium Phosphate (PLGA-B-TCP)

38 a moldable alloplastic graft, Poly Lactic-Co-Glycolic Acid-Coated beta-Tricalcium Phosphate (PLGA-bet

39 nd atactic repeating sequence poly(lactic-co-glycolic acid) copolymers (RSC PLGAs) were prepared and

40 ethylene glycol)-block-poly(lactic acid)-co-(glycolic acid) copolymers underwent macroscopic phase se

41 ne provide access to fully substituted alpha-glycolic acid derivatives bearing a beta-stereocenter.

42 o poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) diblock copolymer NPs.

43 r 7-loaded galactosylated poly(DL-lactide-co-glycolic acid) (FGF7-GAL-PLGA) particles; 26-um diameter

44 were created by coating PLGA (poly[lactic-co-glycolic acid]) films containing test compounds with pHE

45 mpare favourably with current poly-lactic-co-glycolic acid fixation systems, however, silk-based devi

46 rous silica nanoparticles and poly(lactic-co-glycolic acid) for the delivery and controlled release o

47 of this study was to evaluate the effects of glycolic acid (GA) (with pH 1.2 and 5) and ethylenediami

48 acid, glycolaldehyde, glyoxal, acetic acid, glycolic acid, glyceraldehyde, 2-hydroxypropanedialdehyd

49 As little as 10 pg of standard glycolic acid (glycolate) was detected in a method compr

50 esulted in the selective formation of lactic/glycolic acid glycosides, thereby retaining unique infor

51 ocompatible polymers, such as polylactic and glycolic acid, in order to form stable nanoparticles abl

52 ifferent PLGA molar ratios of lactic acid to glycolic acid (L/G) were included.

53 nto valuable C2, C3, and C4 products such as glycolic acid, lactic acid, 2-hydroxy-3-butenoic acid, 2

54 nd dicarboxylic acids (HOOC-R-COOH), such as glycolic acid, lactic acid, glyceric acid, oxalic acid,

55 depot of low molecular weight poly(lactic-co-glycolic) acid (LWPLGA) for sustained delivery GLP-1 and

56 ly(L-lactic acid) and had poly(D,L-lactic-co-glycolic acid) membranes of different molecular masses c

57 ol) dissolution, the flexible poly(lactic-co-glycolic acid) mesh conforms to the resected tumour cavi

58 he form of a micrometre-sized poly(lactic-co-glycolic acid) mesh laid over a water-soluble poly(vinyl

59 rapid prime-boost protocol of poly(lactic-co-glycolic) acid microparticles and a replication-defectiv

60 Using poly(DL-lactic acid-co-glycolic acid) microparticles (MPs) with an average diam

61 Apelin-13 encapsulated in poly(lactic-co-glycolic acid) microparticles displayed a sustained rele

62 Poly(lactic-co-glycolic acid) microparticles prolonged the apelin relea

63 Dexamethasone-releasing PLGA poly(lactic-co-glycolic acid) microsphere/PVA (polyvinyl alcohol) hydro

64 Dexamethasone-releasing poly(lactic-co-glycolic acid) microspheres/polyvinyl alcohol hydrogel c

65 contraception by formulating poly(lactic-co-glycolic acid) MNs to slowly release the contraceptive h

66 at substitution of the 5'-sulfate in 1 for a glycolic acid moiety in 2 maintains kinesin inhibition.

67 ng a quaternary stereocenter and a protected glycolic acid moiety, which are useful building blocks f

68 prepared from the bioassimilable lactic and glycolic acid monomers for biomedical applications makes

69 rating peptide (CPP)-assisted poly(lactic-co-glycolic acid nanoparticles (PLGA NPs), for improving do

70 then engineered lipid-coated poly(lactic-co-glycolic acid) nanoparticles (NPs) with fibrotic kidney-

71 icity, bevacizumab-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles (PLGA NP) were developed an

72 s remote loading method using poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) to load myelin o

73 ncapsulated in biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NP), administered by

74 uch as FDA approved pegylated poly(lactic-co-glycolic acid) nanoparticles (PLGA-PEG-NP) has significa

75 mmunotherapy using CpG-coated poly(lactic-co-glycolic acid) nanoparticles containing peanut extract (

76 tion with AQP4201-220-coupled poly(lactic-co-glycolic acid) nanoparticles could both prevent and effe

77 s method, we found that 80 nm poly(lactic-co-glycolic acid) nanoparticles had maximal K(trans) in a T

78 this study, mannose-decorated poly(lactic-co-glycolic acid) nanoparticles loading with R848 (Man-pD-P

79 Poly(lactic-co-glycolic acid) nanoparticles were dispersed in aldehyde-

80 ted in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce glut

81 degradable polylactic acid and polylactic-co-glycolic acid needles, and its application for the conti

82 m polymeric NPs, specifically poly(lactic-co-glycolic acid) NPs loaded with enrofloxacin (PLGA-Enro N

83 compared to similarly sized poly (lactic-co-glycolic acid) particles.

84 e poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) (PEG-PLGA) copolymers have been used succ

85 radable poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) microparticles were engineered

86 growth factor (PCL-NGF) and a poly(lactic-co-glycolic acid) pellet containing glutamine (PLGA-GLN) we

87 Poly(glycolic acid) (PGA) fiber scaffolds were wrapped around

88 lactic acid (PLA)/poly (d)(,)(l)(-)lactic-co-glycolic acid (PLGA) (75:25 w/w) or PHB as encapsulants.

89 ting consisted of absorbable poly-lactide-co-glycolic acid (PLGA) and crystalline sirolimus deposited

90 We created coils with a 50:50 poly-dl-lactic glycolic acid (PLGA) coating that released MCP-1 at 3 di

91 boxymethyl chitosan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing localized chemo-

92 cation techniques: PEGylation and Polylactic glycolic acid (PLGA) microencapsulation.

93 self-healing capacity of poly (DL)-lactic-co-glycolic acid (PLGA) microspheres containing glycosamino

94 conjugated on the surface of poly-lactic-co-glycolic acid (PLGA) nanoparticles for the protection of

95 yvitamin D(3) encapsulated in poly lactic-co-glycolic acid (PLGA) nanoparticles loaded in Pluronic F1

96 ery of FDA-approved pegylated poly lactic-co-glycolic acid (PLGA) nanoparticles loaded with anticance

97 Lycopene-loaded polylactic-co-glycolic acid (PLGA) NPs were prepared by the same metho

98 osteoconducive apatite-coated Poly-lactic-co-glycolic acid (PLGA) scaffold for cell delivery.

99 situ-forming implant based on polylactic co glycolic acid (PLGA) was chosen in this preclinical stag

100 Poly lactic-glycolic acid (PLGA)- polyethylene glycol (PEG)-based po

101 onor template encapsulated in Poly Lactic-co-Glycolic Acid (PLGA)-based nanoparticles can correct sic

102 ic acid) peptide-modified polylactic acid-co-glycolic acid (PLGA)-Chitosan nanoparticle (CSNP) for in

103 aded polyethylene glycol-poly lactic acid-co-glycolic acid (PLGA-PEG) polymeric nanoparticles (ARV-NP

104 ulating econazole-impregnated poly(lactic-co-glycolic) acid (PLGA) films in poly(hydroxyethyl methacr

105 polymer coating consisting of poly(lactic-co-glycolic) acid (PLGA) microsphere dispersed in poly(viny

106 locally-delivered Scl-Ab via poly(lactic-co-glycolic) acid (PLGA) microspheres (MSs) was compared at

107 Biodegradable poly (lactic-co-glycolic) acid (PLGA) microspheres, encapsulated within

108 Poly(d,l-lactic-co-glycolic) acid (PLGA) nanoparticles containing phenolic

109 micrometer-sized agent-doped poly(lactic-co-glycolic) acid (PLGA) particles by using a single-emulsi

110 and functionalization of poly (D,L-lactic-co-glycolic) acid (PLGA) particles to enhance cell attachme

111 e) into biodegradable polymer poly(lactic-co-glycolic) acid (PLGA) using an electrojetting technique.

112 tible, the US-FDA-approved, poly(l-lactic-co-glycolic) acid (PLGA) was used to engineer nanoparticles

113 4) and TLR7/8 encapsulated in poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles (NPs) induce r

114 eveloped P-selectin-targeted poly (lactic-co-glycolic) acid (PLGA)-poly (ethylene glycol) (PEG)-based

115 Poly(lactic-co-glycolic)acid (PLGA) microspheres containing anti-VEGF R

116 ed after sputtering revealing poly(lactic-co-glycolic) acid(PLGA).

117 g-acting parenterals, such as poly(lactic-co-glycolic acid) PLGA microspheres.

118 (PCL) (core layer), a 50:50 poly (lactic-co-glycolic acid) (PLGA) (sheath layer) and a gelatin (inte

119 at use of carboxyl-terminated poly(lactic-co-glycolic acid) (PLGA) allowed encapsulation of DSP into

120 NPS were prepared using poly(lactic-co-glycolic acid) (PLGA) and chitosan.

121 articulate nanocarriers using poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene glycol (PLGA

122 nal hydrolytically degradable poly(lactic-co-glycolic acid) (PLGA) and reactive oxygen species (ROS)-

123 loaded with 50% w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of hig

124 consisting of water-insoluble poly(lactic-co-glycolic acid) (PLGA) and water-soluble polyvinylpyrroli

125 capsulate vaccine antigens in poly(lactic-co-glycolic acid) (PLGA) by simple mixing of preformed acti

126 The important option of poly(lactic-co-glycolic acid) (PLGA) controlled release microspheres ha

127 anoparticles (CSLPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid layer containing do

128 rospheres consisting of a poly(d,l-lactic-co-glycolic acid) (PLGA) core surrounded by a poly(lactic a

129 oparticles composed of PSA or poly(lactic-co-glycolic acid) (PLGA) diffused at least 3,300-fold slowe

130 aling of aqueous pores in poly(D,L-lactic-co-glycolic acid) (PLGA) drug delivery systems has been ide

131 tration with nanoparticles of poly(lactic-co-glycolic acid) (PLGA) encapsulating short interfering RN

132 rospinning, consists of a poly(D,L-lactic-co-glycolic acid) (PLGA) fiber layer sandwiched between two

133 Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable FDA approved po

134 iodegradable polymer films of poly(lactic-co-glycolic acid) (PLGA) is described.

135 Poly(lactic-co-glycolic acid) (PLGA) is used in vivo for various biomed

136 Poly(lactic-co-glycolic acid) (PLGA) long-acting release depots are eff

137 s of 25% (w/w) sirolimus in a poly(lactic-co-glycolic acid) (PLGA) matrix and is spray-coated onto me

138 ibility of intra-articular poly(DL-lactic-co-glycolic acid) (PLGA) microparticle (MP) formulations in

139 ined release nor-LAAM-loaded poly (lactic-co-glycolic acid) (PLGA) microparticles (MP) using a hydrop

140 as encapsulated in degradable poly(lactic-co-glycolic acid) (PLGA) microparticles embedded in the PVA

141 rically uniform, monodisperse poly(lactic-co-glycolic acid) (PLGA) microparticles in a robust high-th

142 rogels were encapsulated with poly(lactic-co-glycolic acid) (PLGA) microparticles loaded with vascula

143 he scaffolds and accommodated poly(lactic-co-glycolic acid) (PLGA) microparticulate systems that cont

144 Eight minocycline loaded poly(lactic-co-glycolic acid) (PLGA) microsphere batches were produced

145 Here, two poly(lactic-co-glycolic acid) (PLGA) microsphere formulations encapsula

146 eloped Sunb-malate loaded poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres (Sunb-malate MS) with

147 Biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres and synthetic long pe

148 is released for 4 weeks from poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in a poly(N-

149 injectable and biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres encapsulating a model

150 of long-acting injectables, poly (lactic-co-glycolic acid) (PLGA) microspheres have been extensively

151 and porosity distributions in poly(lactic-co-glycolic acid) (PLGA) microspheres were characterized us

152 microtubes and NEP1-40 into poly (lactic-co-glycolic acid) (PLGA) microspheres, obviating the need f

153 H inside the aqueous pores of poly(lactic-co-glycolic acid) (PLGA) microspheres, often termed microcl

154 apsulated in glucose-star poly(d,l-lactic-co-glycolic acid) (PLGA) microspheres.

155 icles (LPNs) consisting of poly(DL-lactic-co-glycolic acid) (PLGA) nanocarriers modified with the cat

156 or were entrapped within the poly (lactic-co-glycolic acid) (PLGA) nanoparticle, which was then encap

157 nanocluster over conventional poly(lactic-co-glycolic acid) (PLGA) nanoparticle.

158 were encapsulated within poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (COUR CNPs) to asses

159 act by encapsulating it into Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (FI-PLGA NPs) and ev

160 as to evaluate the ability of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP) to enhance lute

161 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) conjugated to

162 tudy, SV7 was encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) to improve the

163 lation of the compound within poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PLGA-EtNBS) was fou

164 y silent reduced state inside poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PTX-MB@PLGA NPs).

165 proteins formulated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles adjuvanted with poly

166 ery system for siRNA based on poly(lactic-co-glycolic acid) (PLGA) nanoparticles and combined this sy

167 Here we demonstrate that poly(lactic-co-glycolic acid) (PLGA) nanoparticles carrying rapamycin,

168 s, including the widely used poly (lactic-co-glycolic acid) (PLGA) nanoparticles contained in slow-re

169 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing dexametha

170 hibitor 1a,25(OH)(2)D(3) from poly(lactic-co-glycolic acid) (PLGA) nanoparticles embedded in a thermo

171 tential of galantamine-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles for SCI treatment.

172 We selected poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with lutein,

173 Copolymer poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with SA-2 pro

174 inducing adjuvant based on poly(dl-lactic-co-glycolic acid) (PLGA) nanoparticles modified with the ca

175 the activity of the peptide, poly(lactic-co-glycolic acid) (PLGA) nanoparticles were surface-modifie

176 tation, we have prepared poly(lactic acid-co-glycolic acid) (PLGA) nanoparticles with a PEGylated sur

177 t how surface modification of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with peptide ligand

178 encapsulated with drug-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles.

179 ced antigen presentation over poly(lactic-co-glycolic acid) (PLGA) nanoparticles.

180 lated C1 into PEGylated lipid-poly(lactic-co-glycolic acid) (PLGA) nanoscale drug carriers.

181 ties, was encapsulated within poly(lactic-co-glycolic acid) (PLGA) NPs (Api-NPs) for localized delive

182 we report the formulation of poly(lactic-co-glycolic acid) (PLGA) NPs by nanoprecipitation and the a

183 ed fluorescent, biodegradable poly(lactic-co-glycolic acid) (PLGA) NPs in a range of sizes (120-440nm

184 he method was demonstrated on poly(lactic-co-glycolic acid) (PLGA) NPs loaded with coumarin 6 (C6) as

185 Fluorescently-tagged poly(lactic-co-glycolic acid) (PLGA) NPs were loaded with BODIPY, a flu

186 ternative surface coating for poly(lactic-co-glycolic acid) (PLGA) NPs.

187 her the biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) or the biocompatible polymer polye

188 his hypothesis by assembling poly (lactic-co-glycolic acid) (PLGA) particles loaded with thrombin and

189 the hypothesis that inhalable poly(lactic-co-glycolic acid) (PLGA) particles of sildenafil prolong th

190 use of nitrofurantoin loaded poly(lactic-co-glycolic acid) (PLGA) particles to improve delivery to i

191 Spray-dried poly(lactic-co-glycolic acid) (PLGA) peptide-loaded microspheres have d

192 Poly (lactic-co-glycolic acid) (PLGA) supplies lactate that accelerates

193 Drug-free and drug-loaded poly(lactic-co-glycolic acid) (PLGA) sutures were fabricated by electro

194 ribe microspheres composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along wit

195 PEI1.8k was blended with poly(lactic-co-glycolic acid) (PLGA) to enhance electrostatic cellular

196 g and releasing properties of poly(lactic-co-glycolic acid) (PLGA) were approached with the applicati

197 ng" nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) with bright, spectrally defined qu

198 en as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as t

199 priate biodegradable polymer (poly(lactic-co-glycolic acid) (PLGA)), utilization of a pH- and pore-mo

200 rofile for the degradation of poly(lactic-co-glycolic acid) (PLGA), a member of the most widely used

201 encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in childre

202 lymeric implant made from poly(D,L-lactic co glycolic acid) (PLGA), and can be used as a guiding refe

203 ing biocompatible polymer poly(D,L-lactic-co-glycolic acid) (PLGA), ionizable lipid, helper lipid, an

204 Poly(lactic-co-glycolic acid) (PLGA), one of the most important biodegr

205 The NPs consist of poly(D,L-lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and bi

206 meter of 227nm, composed of a poly(lactic-co-glycolic acid) (PLGA)-based core coated with poly(vinyl

207 Injectable poly(lactic-co-glycolic acid) (PLGA)-based in situ forming implants are

208 mployed to manufacture porous poly(lactic-co-glycolic acid) (PLGA)-based intravitreal implants loaded

209 geting miRNA-155 and employed poly(lactic-co-glycolic acid) (PLGA)-based nanoparticle formulation for

210 study, we designed EDV-loaded poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles (NP-

211 ed nanoparticles (NPs) of poly(D,L-lactic-co-glycolic acid) (PLGA)-poly(ethylene glycol) (PEG)-functi

212 trices by incorporating it in poly(lactic-co-glycolic acid) (PLGA).

213 with distinct functions: (i) poly(lactic-co-glycolic acid) (PLGA, P) serving as the main delivery pl

214 olyethylene glycol)-block-poly(D,L-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) sol-gels have been ex

215 ly(ethylene glycol)-block-poly(d,l-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) thermosensitive gel (

216 osed of end-to-end linkage of poly(lactic-co-glycolic-acid) (PLGA), polyethyleneglycol (PEG), and the

217 formulations as well as with poly(lactic-co-glycolic acid)(PLGA)-based microparticles, co-loaded wit

218 id)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid); PLGA-PEG-PLGA) for increasing the retent

219 nd low Mw free acid end-group poly(lactic-co-glycolic acids) (PLGAs) used to achieve continuous pepti

220 of poly(butylcyanoacrylate), poly(lactic-co-glycolic acid), poly(lactic acid) NPs, liposomes and ino

221 peripheral blood EPCs were seeded onto poly (glycolic acid)/poly (4-hydroxybutyrate) scaffolds for 5

222 ured on hydroxyapatite-coated poly(lactic-co-glycolic acid)/poly(L-lactic acid) (HA-PLGA/PLLA) scaffo

223 with a blend of FDA-approved poly lactic-co-glycolic acid-polyethylene glycol (PLGA_PEG) polymer mic

224 into a drug-encapsulating Poly dl-lactic-co-glycolic acid polymer (PLGA), via a double emulsion solv

225 a unique hexadentate-polyD,L-lactic acid-co-glycolic acid polymer chemically conjugated to PD98059,

226 S contrast agent composed of poly-lactide-co-glycolic acid polymeric (PLGA) microspheres (2-micron di

227 stinct compartments namely; poly(l-lactic-co-glycolic acid) polymeric core acting as a drug reservoir

228 PLGAs as a function of time and PLGA lactic/glycolic acid ratio.

229 nal properties were studied at two lactic to glycolic acid ratios (50:50 and 65:35).

230 an random copolymers with the same lactic to glycolic acid ratios as demonstrated by molecular weight

231 ain an ester linkage between a threonine and glycolic acid residue and an N-terminal FITC fluorophore

232 Installation of the glycolic acid residue followed by C12 epimerization.

233 Self-healing of pores in Poly(lactic-co-glycolic acid)s (PLGA) plays an important role in the en

234 at hydrolytic degradation of poly(lactic- co-glycolic acid)s is dramatically affected by sequence.

235 lylysine around a salt-leached polylactic-co-glycolic acid scaffold that is degraded in a sodium hydr

236 orated in a uniquely designed poly(lactic-co-glycolic) acid scaffold, a clinically safe polymer, foll

237 al (3D)-printed biodegradable poly(lactic-co-glycolic acid) scaffolds (PLGA), and hydroxyapatite powd

238 Specifically labeled deuterated lactic and glycolic acid segmers were likewise prepared and polymer

239 bic acid (AA) in the core and poly(lactic-co-glycolic acid) shell incorporating iron oxide nanocubes

240 Semisynthetic modification of its glycolic acid subunit at C14 provided the first analogs

241 he OS studied include the potassium salts of glycolic acid sulfate, hydroxyacetone sulfate, 4-hydroxy

242 a well-studied biodegradable poly(lactic-co-glycolic acid) support membrane.

243 -lactic acid) (PLA), and poly(lactic acid-co-glycolic acid) surfaces.

244 ion as a synthetic equivalent to the dipolar glycolic acid synthon, the glyoxylate anion synthon, or

245 ibes the use of silyl glyoxylates as dipolar glycolic acid synthons in a controlled oligomerization r

246 icle formulations composed of poly lactic-co-glycolic acid take too long to release encapsulated payl

247 amidoamine dendrimers and poly(d,l-lactic-co-glycolic acid) that demonstrate adjuvant properties in v

248 Poly(lactic-co-glycolic acid) thin films were used to deliver FTY720, a

249 the synthesis of alternating poly(lactic-co-glycolic acid) via a regioselective ring-opening polymer

250 Biocompatible poly (lactic-co-glycolic acid) was selected as the polymer shell to enca

251 of 90% hydroxyapatite and 10% poly(lactic-co-glycolic acid) were printed using a microextrusion proce

252 n-approved 500nm carboxylated-poly(lactic-co-glycolic) acid, were infused intravenously into wild-typ

253 e developed a scaffold from variants of poly(glycolic) acid which were braided and coated with an ela

254 ne cores and shells made from poly(lactic-co-glycolic acid) with varying degradability kinetics-for t

255 Nanoparticles composed of poly(lactic-co-glycolic acid), with polyethylene glycol coatings to res

256 ISFIs were formed using poly(lactic-co-glycolic) acid, with a molecular weight of either 15 kDa